No benefit from TMZ treatment in GB with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB patients.

Monika E HegiFelix B OppongJames R PerryWolfgang WickRoger HenrikssonNorman J LaperriereThierry GorliaAnnika MalmströmMichael Wellernull nullnull nullnull nullnull null

Published in: Neuro-oncology (2024)

For evidence-based treatment of glioblastoma patients validated MGMTp methylation assays should be used that accurately identify truly unmethylated patients. Respective stratified management of patients will reduce toxicity without compromising outcome and allow testing of more promising treatment options.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
dna methylation
randomized controlled trial
gene expression
transcription factor
genome wide
high throughput
middle aged
open label